Indolent Systemic Mastocytosis
📧 Sign up to get email alerts when something new happens for Indolent Systemic Mastocytosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)
An observational study in participants with Indolent Systemic Mastocytosis (ISM) is currently in recruitment. The sponsor is Blueprint Medic…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis [Phase 2, Phase 3]
A clinical trial update describing the ongoing HARBOR study evaluating BLU-263 versus placebo in patients with indolent systemic mastocytosi…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany
A non-interventional study in Germany is currently recruiting participants with indolent systemic mastocytosis to collect observational data…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis [Phase 2]
Phase 2 clinical trial update evaluating CGT9486 vs placebo in indolent or smoldering systemic mastocytosis. The study is currently active b…
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis [Phase 2]
The document outlines a Phase 2 clinical trial, PIONEER, evaluating the efficacy and safety of avapritinib versus placebo in patients with i…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-05-10Clinical Trial Update: Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis [Phase 2]
Phase 2 study of TL-895 in patients with myelofibrosis or indolent systemic mastocytosis is currently recruiting.